<DOC>
	<DOCNO>NCT02180217</DOCNO>
	<brief_summary>The study aim confirm long-term efficacy safety LCI699 treatment patient Cushing 's disease . It pivotal trial intend support registration LCI699 treatment patient Cushing 's disease EU , Japan , country .</brief_summary>
	<brief_title>Safety Efficacy LCI699 Treatment Patients With Cushing 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Male female patient age 1875 year Patients must confirm Cushing 's disease persistent recurrent evidence : 1. mUFC &gt; 1.5 x ULN ( mean three 24hour urine sample collect within 14 day ) 2. morning plasma ACTH low limit normal 3. confirmation pituitary source excess ACTH define follow three criterion : ( 1 ) MRI confirmation pituitary adenoma &gt; 6 mm ; OR ( 2 ) bilateral inferior petrosal sinus sampling ( BIPSS ) either CRH DDAVP stimulation patient tumor &lt; /= 6mm . The criterion confirmatory BIPSS test following : predose central peripheral ACTH gradient &gt; 2 ; postdose central peripheral ACTH gradient &gt; 3 either CRH DDAVP stimulation ; OR ( 3 ) histopathologic confirmation ACTHstaining adenoma patient prior pituitary surgery . Patients history prior pituitary surgery must least 30 day postsurgery eligible inclusion study . Use investigational durgs time enrollment , within 30 day 5 halflives time enrollment , whichever longer ; longer require local regulation , limitation participation investigational trial base local regulation . history hypersensitivity LCI699 drug similar chemical class . hisotry malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metasteses . patient risk factor QTc prolongation Torsade de Pointes , include : patient baseline QTcF &gt; 470ms , personal famiily history long QT syndrome , concomitant medication know prolong QT interval , hypokalemia , hypocalcaemia , hypomagnesemia . Pregnant nursing ( lactate ) woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>LCI699</keyword>
	<keyword>Cushing 's disease</keyword>
</DOC>